Genetic Polymorphisms Predict Chemotherapeutic Outcomes in Patients With Metastatic Breast Cancer
NCT01199393 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 153
Last updated 2015-07-29
Summary
The investigators want to research whether genetic polymorphisms of drug-metabolizing enzymes can be used to predict chemotherapeutic outcomes in patients with metastatic breast cancer.
Conditions
- Breast Neoplasm
- Drug Therapy
- Polymorphism,Single Nucleotide
Sponsors & Collaborators
-
Peking University Cancer Hospital & Institute
lead OTHER
Principal Investigators
-
Ningning Dong, PhD · Peking University Cancer Hospital & Institute
-
Jun Jia, MD · Peking University Cancer Hospital & Institute
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-08-31
- Primary Completion
- 2014-12-31
- Completion
- 2015-05-31
Countries
- China
Study Locations
More Related Trials
-
Genes That Affect Disease Progression in Women With Newly Diagnosed or Metastatic Breast Cancer
NCT00463034 ·Status: UNKNOWN
-
Familial Breast Cancer in China
NCT06833216 ·Status: NOT_YET_RECRUITING
-
Studying Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers
NCT00897455 ·Status: UNKNOWN
-
Genetic Studies in Breast Cancer
NCT00582322 ·Status: COMPLETED
-
Mutation of BRCA1/2 and Other Potential Genes in Triple-negative Breast Cancer
NCT02670668 ·Status: UNKNOWN ·Phase: NA
-
Homologous Recombination Repair Pathway Gene Mutation Spectrum in Chinese Breast Cancer Patients
NCT05901025 ·Status: NOT_YET_RECRUITING
-
Integrating Molecular Pathology, Radiology, and Genetics to Improve Breast Cancer Risk
NCT07207564 ·Status: RECRUITING
-
Prognosis and Targeted Therapy Related Molecular Screening Program for Patients of Breast Cancer in China
NCT03792529 ·Status: UNKNOWN
-
Breast Cancer Molecular Analysis Protocol
NCT01855503 ·Status: COMPLETED
-
Multiplex Testing for Breast Cancer Susceptibility: A Pilot Study of Subject Preferences for Information and Responses After Testing
NCT01992471 ·Status: COMPLETED
-
Evaluation of the Predictive and Prognostic Value of Germ-line Polymorphisms in Patients With Metastatic Breast Cancer
NCT01460186 ·Status: COMPLETED ·Phase: NA
-
Survival of BCS vs Mx in Asymptomatic Screen-detected NPBC
NCT06103032 ·Status: COMPLETED
-
Polymorphism Interaction to Predict Bevacizumab Efficacy
NCT01935102 ·Status: COMPLETED
-
Protocol for Postmenopausal Women at Increased Risk of Developing Breast Cancer
NCT00329017 ·Status: WITHDRAWN
-
Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers
NCT00899145 ·Status: WITHDRAWN
-
Understanding Decision Making Processes for Undergoing Genetic Testing Among Women With Newly Diagnosed Breast Cancer
NCT01386411 ·Status: COMPLETED
-
Detection and Analysis of MBC With Heterogeneous ER Expression
NCT05392985 ·Status: COMPLETED
-
Dynamic Monitoring of HER2 and ctDNA Specific Mutations in Patients With Recurrent or Metastatic Breast Cancer by Digital PCR
NCT03947736 ·Status: UNKNOWN
-
99mTc-ABH2 SPECT/CT in Breast Cancer
NCT06194565 ·Status: RECRUITING ·Phase: NA
-
Knowledge and Attitudes of Patients and Healthcare Professionals on a Spectrum of Genetic Tests Relevant to Breast Cancer Patients
NCT01619306 ·Status: UNKNOWN
-
Susceptibility to Breast Cancer
NCT00004565 ·Status: COMPLETED
-
Protocol to Examine Methylation of Tumor Suppression Genes in Women at High Risk of Developing Breast Cancer
NCT00323908 ·Status: COMPLETED
-
Genetic Alteration After Systemic Treatment in Breast Cancer
NCT02591966 ·Status: UNKNOWN
-
Transcriptional and Epimetabolic Profile of Breast Carcinoma With Luminal or HER2+ or Locally Advanced Triple-negative Histotype in Patients With/Without Previous Clinical History of Metabolic Syndrome
NCT06261918 ·Status: RECRUITING
-
Development of Multi-specific Antibodies Based on Immune Microenvironment of Breast Cancer
NCT05767931 ·Status: UNKNOWN